Yoğun Bakımda Antitrombotik İlaç Kullanımı
Özet
Yoğun bakım hastalarında, koagülasyon ile antikoagülasyon arasındaki dengenin bozulması sonucu venöz ve arteryel tromboembolik olay riski artmakta, bu durum morbidite ve mortaliteyi yükseltmektedir. Bu olayları önlemek veya tedavi etmek amacıyla kullanılan antitrombotik ilaçlar; antikoagülanlar, antiagreganlar ve trombolitikler olarak üçe ayrılır. Antikoagülanlar (standart heparin, düşük molekül ağırlıklı heparinler ve fondaparinuks), pıhtılaşma kaskadını inhibe ederek yeni pıhtı oluşumunu önler ve hemen hemen tüm yoğun bakım hastalarında profilaktik olarak başlatılmalıdır. Antiagreganlar (aspirin, klopidogrel, prasugrel ve tikagrelor), trombosit agregasyonunu engelleyerek özellikle kardiyovasküler ve serebrovasküler arteryel tromboz tedavisinde kullanılır. Trombolitik ajanlar (alteplaz, tenekteplaz, reteplaz ve streptokinaz) ise akut miyokard enfarktüsü ve masif pulmoner emboli gibi acil durumlarda damarı tıkayan pıhtıyı eritmek için tercih edilir. Bu ilaçların kullanımı sırasında hastanın klinik durumuna, böbrek yetmezliği düzeyine ve kanama riskine göre hassas doz ayarlamaları yapılması hayati önem taşır.
In critically ill patients, the disruption of the balance between coagulation and anticoagulation increases the risk of venous and arterial thromboembolic events, leading to higher morbidity and mortality. Antithrombotic drugs, used to prevent or treat these events, are divided into three groups: anticoagulants, antiplatelets, and thrombolytics. Anticoagulants (unfractionated heparin, low-molecular-weight heparins, and fondaparinux) prevent new clot formation by inhibiting the coagulation cascade and should be initiated prophylactically in almost all intensive care patients. Antiplatelets (aspirin, clopidogrel, prasugrel, and ticagrelor) prevent platelet aggregation and are primarily used in the treatment of arterial thrombosis in cardiovascular and cerebrovascular diseases. Thrombolytic agents (alteplase, tenecteplase, reteplase, and streptokinase) are preferred in emergencies such as acute myocardial infarction and massive pulmonary embolism to dissolve the clot obstructing the vessel lumen. During the administration of these medications, making precise dosage adjustments based on the patient's clinical status, level of renal impairment, and bleeding risk is of vital importance.
Referanslar
Tapson VF, Shirvanian S. Anticoagulation. In: Oropello JM, Pastores SM, Kvetan V. eds. Critical Care. McGraw Hill; . Accessed November 22, 2021. https://accessmedicine.mhmedical. com/content.aspx?bookid=1944§ionid=143517960
Vincent JL. Venous Thromboembolism in Medical-Surgical Critically Ill Patients. In: Robert J.W. LKM, editor. Textbook of Critical Care. PA: Elsevier. 2017: 971-975.
Di Nisio M, Porreca E. Prevention of venous thromboembolism in hospitalized acutely ill medical patients: focus on the clinical utility of (low-dose) fondaparinux. Drug design, development and therapy. 2013;7:973.
Hirsh J, Anand SS, Halperin JL, Fuster V. Guide to anticoagulant therapy: Heparin: a statement for healthcare professionals from the American Heart Association. Circulation. 2001;103(24):2994-3018.
Eikelboom JW, Hirsh J. Monitoring unfractionated heparin with the aPTT: time for a fresh look. Thrombosis and haemostasis. 2006;96(11):547-52.
PROTECT Investigators for the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group. “Dalteparin versus unfractionated heparin in critically ill patients.” New England Journal of Medicine 364.14 (2011): 1305-1314.
Bates SM, Middeldorp S, Rodger M, James AH, Greer I. Guidance for the treatment and prevention of obstetric-associated venous thromboembolism. Journal of thrombosis and throm bolysis. 2016;41(1):92-128.
https://www.uptodate.com/contents/image?imageKey=HEME%2F122945
Dager WE GM, Nutescu EA. Anticoagulation Therapy: A Clinical Practice Guide. 2nd ed. American Society of Health-System Pharmacists; 2018.
Holzheimer RG. Low-molecular-weight heparin (LMWH). Eur J Med Res. 2004;2004(9):150-70.
Erkens PM, Prins MH. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database of Systematic Reviews. 2010(9).
Buller HR DB, Decousus H, et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003;349: 1695-702.
https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects
Jones R, Arps K, Davis D, Blumenthal R, Martin SJAJoC. Clinician guide to the ABCs of primary and secondary prevention of atherosclerotic cardiovascular disease. 2018.
Layne K, ferro A. Antiplatelet therapy in acute coronary syndrome. European Cardiology Review, 2017, 12.1: 33.
Hennekens, CH. Update on aspirin in the treatment and prevention of cardiovascular disease. American Journal of Managed Care, 2002; 8.22; SUPP: S691-S700.
Aradı, D. et al. Prognostic significance of high on-clopidogrel platelet reactivity after percu-taneous coronary intervention: systematic review and meta-analysis. American heart journal, 2010, 160.3: 543-551.
Gosling R, Yazdani M, Parviz Y, et al. Comparison of P2Y12 inhibitors for mortality and stent thrombosis in patients with acute coronary syndromes: Single center study of 10 793 consecutive ‘real-world’patients. Platelets. 2017;28(8):767-73.
Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2008;133(6):454S-545S.
Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Res- piratory Society (ERS) The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). 2020;41(4):543-603.
Wang C, Zhai Z, Yang Y, et al. Efficacy and safety of low dose recombinant tissue-type plas minogen activator for the treatment of acute pulmonary thromboembolism: a randomized, multicenter, controlled trial. Chest. 2010;137(2):254-62.
Konstantinides S, Torbicki A, Agnelli G, et al. Corrigendum to: 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. European heart journal. 2015;36(39):2666-2666.
Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocar dial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). European heart journal. 2018;39(2):119-77.
Werf F, Adgey J, Ardissino D, et al. Single bolus tenecteplase compared with front-loaded al teplase in acute myocardial infarction: the ASSENT-2 randomised trial. The Lancet (London). 1999;354:1716-22.
Investigators GA. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. New England Journal of Medicine. 1993;329(22):1615-22.
